Overall, our data demonstrate that SPOP-induced immune surveillance relies on the LMNB2–PD-L1 axis and that the detrimental effects of this axis can be reversed by Atezolizumab in HCC in vitro. Here, LMNB2 is linked to hepatocellular carcinoma.